🏛️ Verified NIH Record • Updated 2026-07-09
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (NCT05634499)
A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Hoffmann-La Roche
🩺 Plain-English Summary (8th-Grade Level)
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.
Who can join: Review the eligibility criteria below.
Location: University of Arkansas for Medical Sciences — Little Rock, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Mount Sinai Medical Center — Miami Beach, Florida
- Minnesota Oncology Minneapolis — Minneapolis, Minnesota
- Englewood Health/Hematology Oncology Practice of Englewood (HOPE) — Englewood, New Jersey
- Western Pennsylvania Hospital — Pittsburgh, Pennsylvania
- Texas Oncology, P.A. - Fort Worth — Fort Worth, Texas
- Virginia Oncology Associates — Norfolk, Virginia
- Jewish General Hospital — Montreal, Quebec
- McGill University Health Centre - Glen Site — Montreal, Quebec
- Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS — Meldola, Emilia-Romagna
- Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice — Gliwice,
- Swietokrzyskie Centrum Onkologii — Kielce,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Cancer
- Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation — Lexington, Kentucky
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Mobile, Alabama
- Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer — Houston, Texas
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line — Garran,
- Activity and Cancer Survivorship Exercise Pilot — Iowa City, Iowa
Explore by condition: All Endometrial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.